Drugs / CHF 5993
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02359292 | Feb → Apr 2015 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07546981 | Jun 2026 → Oct 2028 expected | asthma | Chiesi Farmaceutici S.p.A. | Recruiting | No outcome recorded |
| Phase 3 | NCT06264674 | Nov 2023 → Feb 2025 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT02579850 | May 2015 → Jul 2017 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02743013 Comparator | Apr → Jul 2016 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05018598 Comparator | Feb 2022 → Apr 2024 | asthma | Chiesi Farmaceutici S.p.A. | Terminated | No outcome recorded |
| Phase 4 | NCT05097014 Comparator | Oct 2021 → Feb 2023 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHF 5993 | “Comparing CHF 5993 100/6/12.5 μg pMDI (Fixed Combination of Extrafine Formulation of Beclometasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide)” NCT05018598 ↗7“The purpose of this phase IV Study is to compare the efficacy of CHF5993 (BDP/FF/GB 100/6/12.5 pMDI) on uncontrolled asthma subjects” NCT05018598 ↗ |
| Modality | Other / unclassified | “a single-inhaler triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G)” PMID 29429593 ↗ Feb 2018 |
| Route | Inhaled | “administered 2 puffs twice daily via pMDI” NCT02579850 ↗ |